Professional
Added to YB: 2024-11-08
Pitch date: 2024-10-16
EXAS [bullish]
Exact Sciences Corporation
+43.83%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.
Market Cap
$12.7B
Pitch Price
$70.57
Price Target
N/A
Dividend
N/A
EV/EBITDA
96.85
P/E
-12.73
EV/Sales
4.62
Sector
Biotechnology
Category
growth
Show full summary:
Columbia Acorn Fund Portfolio Holding: Exact Sciences Corporation
EXAS: Cologuard maker rebounded on strong Q results, esp. profitability. Blood-based test shows promise vs peers. $20B+ TAM, double-digit rev growth, expanding margins. Cologuard Plus launch to boost effectiveness. Sentiment improving with blood test progress, despite inferiority to Cologuard.
Read full article (1 min)